Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
WKHS$2.87+0.33(+12.99%)Workhorse Enters Modular AI Infrastructure Market Through Foundational TerraPod™ Partnership with UK-Based RHAELM[4:01:00 PM ET]BBIO$71.44+0.62(+0.88%)BridgeBio Reports Third Quarter 2026 Financial Results and Corporate Updates[4:01:00 PM ET]PRKR$0.07-0.01(-7.44%)William G Walters Joins ParkerVision Board of Directors[4:01:00 PM ET]ALHC$7.35-0.83(-10.16%)Alignment Healthcare Reports Third Quarter 2026 Results, Updates Full-Year Outlook[4:01:00 PM ET]HR$18.13+0.60(+3.42%)Healthcare Realty Reports Third Quarter 2026 Results and Further Increases Full Year 2026 Guidance[4:01:00 PM ET]ATLC$98.15+6.51(+7.10%)Atlanticus to Host Third Quarter 2026 Earnings Call and Webcast on November 5, 2026, at 5:00 p.m. ET[4:01:00 PM ET]MPWR$1,258.90+47.68(+3.94%)Monolithic Power Systems Announces Appointments of Chief Financial Officer and Chief Accounting Officer[4:01:00 PM ET]MPWR$1,258.90+47.68(+3.94%)Monolithic Power Systems Reports Third Quarter Results on October 29, 2026[4:01:00 PM ET]SYM$38.15-0.82(-2.10%)Symbotic Announces Date for Reporting Fourth Quarter and Fiscal Year 2026 Financial Results[4:01:00 PM ET]PFS$23.17+0.05(+0.22%)Provident Financial Services, Inc. Declares Quarterly Cash Dividend[4:00:00 PM ET]PDEX$61.60-1.59(-2.52%)Pro-Dex, Inc. Announces Fiscal 2027 First Quarter Results[4:00:00 PM ET]UNIF$4.020.00(0.00%)U & I Financial Corp. Reports Third Quarter 2026 Financial Results[4:00:00 PM ET]ASMB$20.86+0.29(+1.41%)Assembly Biosciences Doses First Two Participants in Phase 2 Study of Oral NTCP Inhibitor ABI-6250 for Chronic Hepatitis Delta Virus[4:00:00 PM ET]MDXH$0.18-0.01(-5.63%)Mdxhealth to Release Third Quarter 2026 Financial Results on November 12[4:00:00 PM ET]BAFN$6.17-0.24(-3.74%)BayFirst Financial Corp. Reports Third Quarter 2026 Results[4:00:00 PM ET]

ALKS · NASDAQ

Alkermes plc

$45.37 +0.12 (+0.27%)

Company overview

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol dependence and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia and schizoaffective disorder; and VUMERITY for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$7.6B
Employees
2,095
Headquarters
Dublin
Website
alkermes.com
CEO
Richard F. Pops
Listed
July 16, 1991
P/E
48.80
Dividend yield
0.00%

Company financials

Revenue
$1.6B
Gross profit
$1.4B
Operating income
$192M
EBITDA
$276M
Net income
$153M
EPS
$0.93
Total assets
$4.3B
Total debt
$1.6B
Gross margin
86.63%
Net margin
9.78%
Earnings yield
2.05%

Revenue segmentation

By product (FY 2025)
By region (FY 2025)

Showing FY 2025

Price chart

31.9238.0944.2550.4256.58
ALKS 1D NASDAQ O43.66H45.29L43.45C45.25+0.93 (+2.10%)Vol1.44M

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
Ticker Type Headline Source Published
ALKSAlkermes plc Stock news Alkermes Q3 Preview: The Pipeline Looks Strong, But Earnings Tell Another Story Seeking Alpha
ALKSAlkermes plc Stock news Alkermes plc $ALKS Shares Sold by State of Alaska Department of Revenue Defense World
ALKSAlkermes plc Press release Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at Sleep Europe 2026, Underscoring Leadership in Sleep Medicine Research Business Wire
ALKSAlkermes plc Stock news LQDA versus ALKS: Which Biotech Stock Is the Better Buy Now? Zacks Investment Research
ALKSAlkermes plc Stock news Alkermes: Idiopathic Hypersomnia Could Expand Lumryz Into A Larger Growth And Margin Driver Seeking Alpha
ALKSAlkermes plc Stock news Alkermes Posts Positive Data From Phase I ADHD Study on ALKS 7290 Zacks Investment Research
ALKSAlkermes plc Stock news Meta To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Tuesday Benzinga
ALKSAlkermes plc Stock news How Alkermes Used Its Narcolepsy Playbook In ADHD — And Seemingly Won Investors Business Daily
ALKSAlkermes plc Press release Alkermes Announces Positive Phase 1b Results Demonstrating Clinical Proof-of-Concept for ALKS 7290 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD) Business Wire
ALKSAlkermes plc Stock news Alkermes Announces Appointment of Anne C. Whitaker to Board of Directors Business Wire
ALKSAlkermes plc Stock news California State Teachers Retirement System Increases Holdings in Alkermes plc $ALKS Defense World
ALKSAlkermes plc Stock news Alkermes: A Slow-Burning Buy Prospect On Orexin-Agonist Promise Seeking Alpha
ALKSAlkermes plc Stock news Alkermes Announces Launch of 9th Annual Alkermes Pathways Research Awards® Program Business Wire
ALKSAlkermes plc Stock news Financial Review: C4 Therapeutics (NASDAQ:CCCC) and Alkermes (NASDAQ:ALKS) Defense World
ALKSAlkermes plc Stock news Alkermes Chief Commercial Officer Sells 7,576 Shares for $373,000 The Motley Fool
ALKSAlkermes plc Stock news Why Is Alkermes (ALKS) Up 1.7% Since Last Earnings Report? Zacks Investment Research
ALKSAlkermes plc Press release The Lancet Neurology Publishes Data From Alkermes' Positive Vibrance-1 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 1 Business Wire
ALKSAlkermes plc Stock news Bank of America Corp DE Trims Position in Alkermes plc $ALKS Defense World
ALKSAlkermes plc Stock news ALKS Stock Rises 27% in 3 Months: Here's What You Should Know Zacks Investment Research
ALKSAlkermes plc Stock news Alkermes (ALKS) Expected to Beat Earnings Estimates: Can the Stock Move Higher? Zacks Investment Research
See more
FAQ

Questions about Alkermes plc

What does Alkermes plc do?
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol dependence and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia and schizoaffective disorder; and VUMERITY for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.
What is ALKS's market cap?
Alkermes plc (ALKS) is a listed stock with a live quote. The latest market cap on this page is $7.6B.
Where is Alkermes plc headquartered?
Alkermes plc is headquartered in Dublin.
How do I get ALKS news from the API?
Call GET /v1/news?tickers=ALKS. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.
How far back does ALKS news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for ALKS, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees articles since 2020 as headlines are ingested. A Free API key returns the last year. Pro keys search articles since 2020.
Is the ALKS price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 1,000 REST requests a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs